Search

Your search keyword '"Verri C"' showing total 140 results

Search Constraints

Start Over You searched for: Author "Verri C" Remove constraint Author: "Verri C"
140 results on '"Verri C"'

Search Results

101. Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging.

102. Brucella abortus Induces the Premature Death of Human Neutrophils through the Action of Its Lipopolysaccharide.

103. Emergence of an outbreak-associated Clostridium difficile variant with increased virulence.

104. Localised prostate cancer and hemophilia A (AHA): Case report and management of the disease.

105. Brucella ceti infection in dolphins from the Western Mediterranean sea.

106. YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes.

107. Assessment of circulating microRNAs in plasma of lung cancer patients.

108. Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study.

109. Therapeutic use of microRNAs in lung cancer.

110. Purification of intracellular bacteria: isolation of viable Brucella abortus from host cells.

111. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: surgical, oncological, and functional outcomes: a systematic review.

112. [Intravesical therapy with mitomycin through electromotive drug administration].

113. Brucella ceti and brucellosis in cetaceans.

114. New Bruce-ladder multiplex PCR assay for the biovar typing of Brucella suis and the discrimination of Brucella suis and Brucella canis.

115. MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer.

116. The use of green fluorescent protein as a marker for Brucella vaccines.

117. The two-component system BvrR/BvrS regulates the expression of the type IV secretion system VirB in Brucella abortus.

118. Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk.

120. The differential interaction of Brucella and ochrobactrum with innate immunity reveals traits related to the evolution of stealthy pathogens.

121. Serological diagnosis of Brucella infections in odontocetes.

122. First record of Prorocentrum lima (Dinophyceae) inside harbor areas and along the Abruzzo region coast, W Adriatic.

123. Intracellular adaptation of Brucella abortus.

124. Intravesical electromotive drug administration of mitomycin-C for non-muscle invasive bladder cancer.

125. [Intravesical Electromotive Drug Administration®(EMDA)with Mitomycin-C for non-muscle invasive bladder cancer].

126. Neurobrucellosis in stranded dolphins, Costa Rica.

127. QTc and autonomic neuropathy in diabetes: effects of acute hyperglycaemia and n-3 PUFA.

128. BvrR/BvrS-controlled outer membrane proteins Omp3a and Omp3b are not essential for Brucella abortus virulence.

129. Brucella abortus uses a stealthy strategy to avoid activation of the innate immune system during the onset of infection.

130. R-Ras glucosylation and transient RhoA activation determine the cytopathic effect produced by toxin B variants from toxin A-negative strains of Clostridium difficile.

131. Activation of Rho and Rab GTPases dissociates Brucella abortus internalization from intracellular trafficking.

132. In vivo proteolytic degradation of the Escherichia coli acyltransferase HlyC.

133. Treatment of advanced colorectal and gastric cancer with 5-fluorouracil and calcium n-methyltetrahydrofolate.

134. [Neoplastic occlusions of the large intestine (clinical study)].

136. Human immunoglobulins in the prophylaxis of infections in granulocytopenic neoplastic patients.

137. [Program for the prevention of fetal erythroblastosis].

138. [Glanzman's syndrome (pubertal age)].

139. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin.

140. [5 cases of uterine sarcoma].

Catalog

Books, media, physical & digital resources